Signatera detected 90% of recurrences versus 55% for AMERK. Is Merkel cell surveillance about to change?
Signatera showed 90% sensitivity versus 55% for AMERK in Merkel cell carcinoma, strengthening Natera’s case for broader MRD surveillance.
Pharma & Biotech
Pharma & Biotech
Why this Dana-Farber collaboration is looking beyond survival in metastatic inflammatory breast cancer
Dana-Farber and Ohio State unite to study how local treatment affects quality of life in metastatic inflammatory breast cancer.
Medical Devices & Diagnostics
Leo Cancer Care targets proton therapy access with $65m Series D financing
Leo Cancer Care has raised $65 million in Series D financing to scale its integrated upright cancer care platform, which is designed to image and treat patients in a seated position rather than the conventional lying-down setup. The oversubscribed round supports manufacturing scale-up, commercial deployment and continued development across upright proton therapy, photon therapy and
Medical Devices & Diagnostics
Why Dana-Farber’s Enhertu biomarker study could change metastatic breast cancer diagnostics
Dana-Farber’s new study highlights Ignite Proteomics in Enhertu response prediction. Read what this could mean for metastatic breast cancer care.
Pharma & Biotech
What TAG1’s Lead-212 supply deal with Dana-Farber reveals about the future of radiopharmaceutical oncology
TAG1 and Dana-Farber partner to expand Lead-212 access for targeted alpha therapies. Discover what this means for radiopharmaceutical oncology innovation.
Pharma & Biotech
What the Akeso–INOVIO immunotherapy collaboration signals for the future of glioblastoma clinical research
Akeso and INOVIO test cadonilimab plus INO-5412 in the INSIGhT glioblastoma trial. Explore what this immunotherapy strategy could mean for GBM research.
Medical Devices & Diagnostics
Why 10x Genomics is betting on CLIA lab certification to advance spatial diagnostics in oncology
Find out how 10x Genomics and Dana-Farber aim to transform cancer diagnostics using spatial biology and single cell profiling for real-world clinical decisions.